Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. (Q38187182)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517491%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517491%20AND%20SRC:MED&resulttype=core&format=json

chronic obstructive pulmonary disease

7 March 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517491%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Katharine H Abbott-Banner

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517491%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

6 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517491%20AND%20SRC:MED&resulttype=core&format=json

Basic and Clinical Pharmacology and Toxicology

7 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517491%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517491%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517491%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

365-376

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517491%20AND%20SRC:MED&resulttype=core&format=json

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

COPD exacerbations: defining their cause and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

New concepts in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Oxidative stress and airway inflammation in severe exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Cyclic nucleotide research -- still expanding after half a century

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Phosphodiesterase-4 as a potential drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Type 4A cAMP-specific phosphodiesterase is stored in granules of human neutrophils and eosinophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Modulation of spasmogen-stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Effects of RP 73401, a novel, potent and selective phosphodiesterase type 4 inhibitor, on contractility of human, isolated bronchial muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

PDE4D plays a critical role in the control of airway smooth muscle contraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

A comparison of the relaxant effects of olprinone and aminophylline on methacholine-induced bronchoconstriction in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Transcriptome sequencing (RNA-Seq) of human endobronchial biopsies: asthma versus controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phospho

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Roflumilast inhibits respiratory syncytial virus infection in human differentiated bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Role of phosphodiesterases in the regulation of endothelial permeability in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 strain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Phosphodiesterase inhibitors in the treatment of inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Synthesis and Structure−Activity Relationships of cis-Tetrahydrophthalazinone/Pyridazinone Hybrids: A Novel Series of Potent Dual PDE3/PDE4 Inhibitory Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Zardaverine as a selective inhibitor of phosphodiesterase isozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Subchronic toxicity of orally administered (gavage and dosed-feed) theophylline in Fischer 344 rats and B6C3F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Theophylline-induced mesenteric periarteritis in F344/N rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Antagonism towards endogenous adenosine and inhibition of cGI-PDE in the cardiac effects of amrinone, milrinone and related analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FBCPT.12209

21 January 2018

Identifiers

DOI

10.1111/BCPT.12209

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24517491%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference